YY1 is Pivotal in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target describes the current state-of-the-art of the transcription factor YY1 that is overexpressed in the majority of cancers and a central factor that regulates all of the major features and characteristics of human cancers. This book emphasizes the biochemical, molecular and genetic underlying mechanisms by which YY1 regulates its pro-cancerous activities. In addition, it also describes the role of YY1 in the regulation of tumor cell resistance to conventional chemo and immunotherapies and the important role of inhibiting YY1 in cancer.
This book is a valuable source for cancer researchers, oncologists and several members of medical and biomedical field who are interested in understanding further the role of YY1 in cancer.
- Provides a thorough understanding of the underlying mechanisms by which YY1 regulates cancer cell phenotype and unique characteristics
- Discusses the novel mechanisms of YY1 regulation of tumor cell resistance and means to overcome resistance
- Encompasses new examples of newly developed non-toxic and selective inhibitors targeting YY1
1. General introduction of YY1 2. Expression of YY1 in various human cancers: Prognostic significance 3. Regulation of YY1 transcription and post-transcription 4. YY1 and proliferation 5. Role of microRNAs targeting YY1 6. YY1 repression of various genes in various cancers 7. YY1 regulation of EMT and metastasis 8. YY1 regulation of the cancer stem cell phenotype 9. YY1 regulation of autophagy 10. YY1 regulation of resistance to chemotherapy 11. YY1 regulation of resistance to immunotherapy 12. YY1 phosphorylation 13. YY1 epigenetic regulation 14. YY1 regulation of the Warburg Effect 15. YY1 inhibitors 16. YY1 versus YY2 17. Future perspectives and conclusions
Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press ("Cancer Sensitizing Agents for Chemotherapy, "Breaking Cancer Resistance to Therapeutic Antibodies, and "Breaking Tolerance to Anti-Cancer Immunotherapy) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.